drugset

drugset / Trial / NCT06554795

First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

NCT06554795 ↗

Phase 1/2 Recruiting 360 enrolled DualityBio Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors

Timeline

Start: 2024-09-03
Primary completion: 2027-02
Completion: 2027-02

Publications

Li C, Yao J, Yang J, Zhang Y, Qiu Y, Zhu Z, Hua H. Preclinical Evaluation of DB-1419, a Novel Bifunctional and Bispecific Anti-B7-H3 x PD-L1 Antibody-Drug Conjugate. Clin Cancer Res. 2025 Aug 14;31(16):3581-3593. doi: 10.1158/1078-0432.CCR-25-0634.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DB-1419	Unknown	—	Intravenous

Indications